Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
GAITHERSBURG, Md. - Emergent BioSolutions Inc. (NYSE:EBS), currently undervalued according to InvestingPro analysis with a market capitalization of $385 million, announced Wednesday the expansion of its NARCANDirect online distribution network to include KLOXXADO Nasal Spray 8 mg, a higher-dose prescription emergency treatment for opioid overdoses.
The platform, which already offers NARCAN Nasal Spray 4 mg, provides streamlined access to opioid overdose response products for qualified direct purchasers including emergency services, law enforcement, government agencies, schools, and community-based distribution programs. With a strong current ratio of 6.32, the company maintains robust liquidity to support its distribution expansion efforts.
Emergent acquired exclusive commercial rights to KLOXXADO in the U.S. and Canada in January 2025. The company stated this expansion comes as recent CDC data shows mixed trends in overdose deaths, with provisional data from May showing a 27 percent decrease in drug overdose deaths in 2024, while more recent June data indicated an increase of approximately 1,400 deaths from January 2024 to January 2025.
"Adding KLOXXADO to our NARCANDirect distribution is an important step in broadening access to naloxone and saving more lives," said Paul Williams, senior vice president at Emergent.
The company is also introducing Convenience Kits on the platform, which include a medical-grade CPR mask and nitrile examination gloves in a durable case for overdose response.
NARCAN Nasal Spray 4 mg became the first FDA-approved over-the-counter naloxone product, while KLOXXADO Nasal Spray 8 mg remains available by prescription.
Public interest customers can access these offerings through NARCANDirect.com, according to the press release statement. Despite current challenges reflected in its trailing twelve-month revenue of $965.4 million, analysts tracked by InvestingPro expect positive net income growth this year. Get detailed insights and 8 additional ProTips about EBS’s financial outlook with an InvestingPro subscription, including exclusive access to the comprehensive Pro Research Report covering what really matters about this healthcare stock.
In other recent news, Emergent BioSolutions reported a substantial 656% increase in net income for the first quarter of 2025, reaching $68 million despite a decline in total revenues to $222 million. The company also secured a $62.4 million contract modification from the U.S. Department of Health and Human Services for its botulism antitoxin, reinforcing its role in medical countermeasures. Additionally, Emergent BioSolutions will join the Russell 3000 Index, marking a significant milestone in its market presence. Analysts from H.C. Wainwright highlighted the company’s strategic focus on medical countermeasures and opioid overdose reversal treatments as key drivers of its performance. The firm has also been actively engaging in strategic divestitures and restructuring, reducing operating expenses by 32%. Notably, Emergent BioSolutions has set its 2025 revenue guidance between $750 million and $850 million, with expectations for revenue to be more heavily weighted towards the latter half of the year. The company continues to expand geographically, with significant international sales contributing to its financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.